<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="164631">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01675297</url>
  </required_header>
  <id_info>
    <org_study_id>HL_RSNP_401</org_study_id>
    <nct_id>NCT01675297</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Risedronate, Cholecalciferol Combination Tablet in Patients With Osteoporosis</brief_title>
  <official_title>For 12months, the Multi Center, Randomized, Open-label, Active Controlled Comparative Clinical Study to Assess the Efficacy and the Safety of Risedronate, Cholecalciferol Combination Tablet in Patients With Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanlim Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanlim Pharm. Co., Ltd.</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and the safety of Risedronate,
      cholecalciferol combination tablet in patients with Osteoporosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the efficacy and the safety of Risedronate with and
      without cholecalciferol on vitamin D status, Bone Mineral Density (BMD) and bone markers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The change of Bone Mineral Density (BMD) value</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change of 25OHD(25-hydroxyvitamin D)/PTH(Parathyroid hormone value)</measure>
    <time_frame>6months, one year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1170</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Risendronate/Cholecalciferol combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: Administer Risendronate/Cholecalciferol combination one tablet once a week for 12months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risedronate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active comparator: Administer Risendronate one tablet once a week for 12months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risedronate/Cholecalciferol combination</intervention_name>
    <description>once a week</description>
    <arm_group_label>Risendronate/Cholecalciferol combination</arm_group_label>
    <other_name>RisenexPlus tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risedronate</intervention_name>
    <description>once a week</description>
    <arm_group_label>Risedronate</arm_group_label>
    <other_name>Sedron 35mg tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male osteoporosis patients over 19 years of age

          2. Female osteoporosis patients with menopause

               -  Definition of osteoporosis

                    -  They had a BMD T-score -2.5 or less at mean Lumbar spine(L1-L4), Femoral
                       neck or total. Or evidence of at least one vertebral fracture

               -  Definition of menopause(can be one of three condition)

                    -  For 12months spontaneous amenorrhea

                    -  For 6months spontaneous amenorrhea with serum FSH(Follicle stimulating
                       hormone) is 40mlU/mL and over

                    -  6weeks after bilateral ovariectomy whether hysterectomy or not.

        Exclusion Criteria:

          1. Patients with esophagus disorder (i.e:esophagostenosis)

          2. Patients administered with osteoporosis therapy(except calcium, Vit.D
             medication)within the previous 3 Months

          3. Patients with serum calcium concentrations 8.0mg under

          4. Patients with severe nephropathy (CCr 30mL/min less)

          5. Patients with unable to sit upright or stand for 30minutes
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyoung-Moo Park, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chung-Ang University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Na Hyun Kang</last_name>
    <phone>82-2-3489-6298</phone>
    <email>nahyun.kang@hanlim.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Young Ran Song</last_name>
    <phone>82-2-3489-6297</phone>
    <email>yrsong@hanlim.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chung-ang university hospital</name>
      <address>
        <city>Seoul</city>
        <zip>156-755</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ah Rong Choi, CRC</last_name>
      <phone>8210-2036-4353</phone>
      <email>baby123@naver.com</email>
    </contact>
    <contact_backup>
      <last_name>Nahyun Kang, CRA</last_name>
      <phone>822-3489-6298</phone>
      <email>nahyun.kang@hanlim.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hyoung-Moo Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 17, 2013</lastchanged_date>
  <firstreceived_date>August 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Risedronate, cholecalciferol, BMD</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Risedronic acid</mesh_term>
    <mesh_term>Etidronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
